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Introduction
In many ways, the United States is the Pharmaceutical Capital of the World. Four
out of the top 10 grossing pharmaceutical companies are based in the United States and
the US develops more drugs than any other nation1. Americans also consume more drugs
than almost any other developed nation, at an average of 2.2 prescriptions taken regularly
per capita2. However, the US also spends more on prescription drugs than any other
nation3. The US spends twice the average amount paid by industrialized nations for
pharmaceuticals per capita calculated by the Organization for Economic Co-operation
and Development4. While we have no centralized, single-payer system, our public
expenditure on healthcare overall is comparable with that of most European governments
with single-payer systems (see Appendix 3)5. What distinguishes us from these other
industrialized countries is our massive private expenditure (a combination of premiums,
deductibles, co-pays, and out of pocket costs) on healthcare and prescription drugs, which
exceeds our public expenditure and is more than double the next largest private
contribution6,7. Furthermore, our drug spending has been steeply and steadily rising in
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the last 10 years and is projected to continue rising at higher and higher rates (Appendix
2)8.
America’s high pharmaceutical spending is part of a trend in high healthcare costs
in the United States. The US spends 16.9% of its GDP on health costs, while the OECD
average is 9.3% of GDP.9 Our public expenditure amounts to half of our overall
healthcare costs while the average OECD nation has a 72% public expenditure10.
Similarly, roughly two thirds of our pharmaceutical spending comes from private
insurance and out of pocket spending.11 While the US Government (and thus the
American tax-payer) is paying roughly the same amount per capita as other OECD
nations, American consumers are being asked to pay again through private insurance and
out-of-pocket costs and thus are effectively double charged12,13. What is remarkable
about American healthcare is that, while we pay twice the average of comparable
countries our health outcomes are average at best and by some measures significantly
worse. In 2012, the United States had an average life-expectancy at birth of 78.7 years
compared to the OECD average of 80.2 years, this earned us a ranking of 27th out 34
OECD nations14. Our mortality rate for cardio-vascular disease was 261.2 deaths per
100,000 compared to the average 296.4 deaths per 100,000 landing us a rank of 17/3415.
Mortality from cancer in the US was 198.7 out of 100,000 compared to 213.1, which
8
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placed us at 25/3416. These statistics place us squarely in the middle of the pack, which
might be respectable if we were not paying more than any other comparable country for
our care. And those are our good stats, our obesity rates land us a number one ranking,
meaning we are the most obese of all industrialized nations17. These statistics show that
while we pay more than any other nation, we are not healthier than other nations. So
what are paying for if not health outcomes?
While prescription drugs are not the only expensive aspect of our health system, it
is an aspect that touches the lives of most Americans, it accounts for a large percentage of
our health expenditure, and the costs are prohibitive for many people. 54% of Americans
take at least one prescription drug regularly and many take several drugs regularly18.
Around a quarter of all Americans taking prescription drugs (14% of all Americans)
admit to difficulty affording their medication19. Among uninsured Amerians, 17% stated
that at some point they had forgone, delayed or decreased a prescription dose because of
the cost of their medication20. Even among the insured, 5% report engaging in the same
tactics because of the high prices, this amounts to 1/10 Americans being unable to afford
their prescribed drugs21. Most Americans (72%)—whether or not they are taking drugs
themselves—believe that the costs of pharmaceuticals are too high22.
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It is clear that both compared to other countries and compared to what our own
citizens can afford, the US is facing high costs for pharmaceuticals. The purpose of this
exploration is to determine (1) whether these high costs are ethically justifiable and (2)
who is responsible for making drugs more affrodable. In considering these questions, we
will need to start with a framework for how we consider our pharmaceutical system. In
order to limit the scope of this study and to make any policy recommendations plausible,
we will start with a non-ideal model. There will be no attempt in this paper to
fundamentally restructure the US healthcare or pharmaceutical systems, and all policy
recommendations will maintain the multi-payer healthcare system and the
private/corporate drug industry. Rather, I will look at the industry as it is, consider how
the many facets of our healthcare industry and regulations influence prices and
consumers, and make recommendations to increase or decrease regulations as necessary
to make drugs more affordable. These policy options also will exist within the real
world, and will consist of public and private efforts that could be made at any moment
that the political will should arise.
Since we will be working within the system that already exists, in order to
determine whether prices are justified we must consider what the goals of our system are.
These goals can be summarized by the values of fairness, equity and quality; and in order
for the high prices paid to be ethically justified, the costs must contribute to the
achievement of these goals. The goal of any healthcare system is to maximize population
health by providing accessible, affordable and good quality care that maintains individual
liberty and autonomy in health decisions23. A further goal that should guide all health
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systems is to limit social injustice and maximize social good, while correcting for poverty
and systematic disadvantage24. In America our private pharmaceutical sytems mean that
profits are necessarily a goal. While this is not directly an ethical goal, prices cannot be
justified if they would make pharmaceutical companies unprofitable, because it would
make the achievement of our ethical goals impossible. Problems in setting ethical prices
arrise when there is conflict between our ethical goals or between the ethical goals and
the necessity of profit.
In order to meet the goal of maximizing health, quality prescription drugs must be
fairly and equitably accessible. Quality in this circumstance means a few different
things; at its most basic, it means that the drugs on the market must be safe and effective,
but in broader terms it could mean a duty to create innovative or the most effective drugs
possible. If taken in the broader sense, there is a responsibilty for innovation built into
the requirements for an ethical pharmaceutical system. This seems to be the
interpretation favored by drug companies, and is often used to explain high prices. If
companies are obligated to innovate, then they are justified in charging the prices that are
necessary to fund that innovation. The second duty involved in maximizing health is the
responisibility to make drugs equitably accessible. This duty to equity encompasses the
goals of accessabilty, affordabilty, and correcting for systematic disadvantage. To
accomplish these goals, vital drugs need to be affordable to everyone with no barriers to
access such as limited suppliers or insufficient quantity. Equity can also have a
relationship with price discrimination, which is the practice of charging different buyers
different prices based on their willingness or ability to pay. In order to make drugs fairly
and equitably accessible while maintainging profits a certain amount of price
24
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discrimination may be necessary; but price discrimination should be used in order to
lower what the poorest and most vulnerable pay, not to take advantage of those who lack
barganing power. Here we reach our first problem in justifiying pharmaceutical prices.
If the pharmaceutical industry is producing good quality, life saving, innovative drugs,
but charging prices that are unnaffordable, how can they be justified? What is the highest
priority? It seems fair to say that if one is able to achieve the simultaneous goals of
quality and access then one should be required to do so. Thus, if companies do not need
to charge high prices in order to create quality drugs, than they would not be justified in
pricing people out of their treatments. However, if high prices are necessary in order to
create quality treatments, than the pharmaceutical industry would be justified in charging
a lot, even if it meant that some or even most could not afford it. If this is the case, we
might hope or expect that some other payer, like private insurance, government insurance
or charities might step in to help those with lower incomes afford necessary treatment;
but it would not fall to the company to sacrifice quality for accessibilty. However, this
rests on the supposition that the quality of medication requires high prices.
After considerations of quality and equitable access comes the goal of fairness.
Fairness can mean many things, but in this investigation will be used to describe access to
the conditions and information necessary for patients and buyers of pharmaceuticals to
make informed decisions. Liberty and autonomy are wrapped up in this definition of
fairness, because fairness is necessary for people to make free and autonomous choices
concerning their healthcare. In order for a pharmaceutical system to ensure liberty and
autonomy for consumers there must be adequate information about drugs being sold.
Patients, doctors, hospitals, insurers, and the government are all buyers of
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pharmaceuticals, and are all entitled to sufficient information about the quality and cost
of the products they wish to buy. This information might be about the efficacy of a drug,
the treatment alternatives, the list price and the cost breakdown. A just pharmaceutical
system must make this information available to consumers. Finally, in order to achieve
the ethical goals outlined above, profit is a necessary pragmatic goal in the US
pharmaceutical system. Without sustained profits for companies, they could not continue
to produce drugs and no one would have access to the drugs they make. However, while
it is true that it is in everyone’s interest to ensure that pharmaceutical companies are
making enough profit to stay in business, that does not mean there is an obligation to pay
high prices beyond what it takes to create good quality and widely available drugs.
Some of these goals are not so different from most other consumer industries; in
most purchases, whether it is cars, phones, groceries or clothes, there is a similar balance
to strike. There is an expectation of safety, effectiveness, affordability and profit in all
industries. However, what makes pharmaceuticals and other health industry purchases
different is that the stakes are so much higher for consumers; it is not like buying a new
phone (no matter what certain representatives in Congress might think) because going
without a phone because of its cost is inconvenient but not fatal25. When 10% of
Americans have faced the decision to delay or forgo taking their prescriptions because of
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cost, that is a much greater problem than if 10% are going without the latest iPhone26.
There already exists an intuition in our own country (though it is less developed than in
single payer countries) that no one should be turned away from accessing care; hospitals
cannot turn patients away if they lack money or insurance, and we have many different
systems for providing healthcare for those who cannot afford it. So it does not seem that
there is a strong belief that the poor or the uninsured or the very sick should be deprived
of health services; rather, there are different strategies for improving access. What
further distinguishes the pharmaceutical and broader health industries from other
consumer products is the fact that the buyers of the products are often not the consumers.
With our complicated network of stakeholders, which ranges from the government to
private insurance to private pharmacies to individual patients, the person making the
purchasing decision is rarely the patient alone and so conflicts of interest are bound to
arise.
After we consider how well the pharmaceutical industry is meeting its goals we
need to answer the question of who is responsible for costs. Responsibility can refer to
blame for the state of high prices, but also the duty to remedy the problem. In this ethical
investigation I will touch on the aspect of blame, but will to focus on the duty to act.
After determining whether the prices for drugs are justified, I will set out to find who is
responsible for bringing down costs and making drugs more equitably and fairly
accessible. We cannot assume that drug companies are solely responsible for bringing
down prices, because profit is an intrinsic goal of any company and because they were
not alone in creating the problem of inequitable access. While it is drug companies that

26
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set prices, they did not create the income inequality that causes differing abilities to pay,
so they might argue that it is not their responsibility to make drugs available to the poor
and uninsured. However, if the prices they have set are unjustifiable and they could
create quality drugs that are affordable while still making a profit, then they are not
justified in raising prices to make their products inaccessible. Furthermore, it is not very
realistic for a company providing such a vital service to ignore the economic
disadvantages that do exist. If water companies raised prices and cut off the water of low
income Americans, we would not settle for the explanation that it is income inequality
and not high prices that are causing the water to be shut off. While income inequality is
certainly a problem that should be addressed, it is hard to see how high prices on essential
services do anything to alleviate that problem or the hardships people with low incomes
face. It seems that pharmaceutical companies cannot avoid all responsibility for the
inaccessibility caused by high prices, but their responsibility for ensuring greater
accessibility might be shared. Again, eliminating income inequality is not the most
expedient means of increasing access to pharmaceutical treatments, but income inequality
is clearly exacerbating inequitable access to drugs. So who is responsible for increasing
equity? The government certainly has its share of responsibility, and has acknowledged
that responsibility through programs like Medicaid and Medicare. Individuals by
contributing to government and charitable programs have similarly accepted a
responsibility to improve access. So there are many stakeholders with responsibilities to
improving access, and these responsibilities are rooted in both individual and collective
interests. Individually it is in the interest of most of these stakeholders to make drugs
more widely available. The government and taxpayers would benefit from lower prices

9

since it would lower their health expenditure while improving health. Individual private
expenditure (co-pays, deductibles, and premiums) would be lessened if prices were
lowered, and more people had access to affordable medications. The interest of the
pharmaceutical industry in making drugs more affordable is the least obvious, but it is
still present. Pharmaceutical companies have one of the lowest approval ratings of any
industry, even lower than oil companies, with only 12% of Americans holding a
favorable view of pharmaceutical companies27. Most Americans do not see drug
companies as making significantly greater contributions to quality of life than any other
industry, but they do see them as making too much money and being too focused on
profits28. Taking greater action to make drugs more affordable would not only be a more
sustainable model, but would improve the image of companies tremendously.
In addition to these individual or self-interests in improving pharmaceutical
access, there are also collective reasons why improving access to drugs is a worthy goal.
While lowering costs would be financially beneficial for everyone, it would also improve
the health and lives of those currently struggling to afford their medications. While the
goals of health industries are articulated through quality and access, the overall goal is to
improve health. We have a responsibility to each other and to our collective health. We
saw from the statistics on life expectancy, mortality and morbidity, that we are not doing
a great job of improving the health of our fellow Americans compared to other nations.
Whether we look at these aggregate statistics of health or at the rates of people who
cannot afford medications or at the stories of individuals who struggle to afford
healthcare, it is clear that any collective duty to protect the health of others is being
27
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shirked. But again a problem arises in pinpointing where the responsibility lies in
making drugs affordable when there are so many stakeholders.
In order to investigate pharmaceutical pricing and access and to determine
whether the prices charged are justifiable, we must evaluate how the industry and our
pharmacy benefit system measures up against the goals and responsibilities outlined
above. This will require both empirical and ethical evaluations of the actions of drug
manufacturers, government entities and private insurers. Empirical evaluations are
necessary to consider claims made by pharmaceutical companies that living up to their
quality responsibilities requires high prices, which limit access. Empirical evaluations
are also necessary to understand whether the pharmaceutical industry is truly living up to
its obligations to quality and fairness. To accomplish these empirical and ethical
evaluations I will use a case study method to understand the nuances of pharmaceutical
pricing, the problems created by high costs and the justifications that may exist. The case
studies I will employ are all drugs that have received media attention in the last year
concerning their high cost. While the drugs are all very different, they are all examples
of drugs that have become cost prohibitive. Some of the causes for their high prices
overlap and so do some of the solutions, but they also present unique challenges and
policy ideas. The first case, EpiPen, is a unique pharmaceutical device that can save
patients experiencing anaphylactic shock; yet in the last 10 years the price has gone up
500%, not because of investments in the device, but because of investments in marketing
and lobbying. The second case, Hepatitis C anti-virals, are a very promising new class of
drug with the ability to cure most patients with Hepatitis C; yet the high price tag has the
potential not only to bankrupt individual patients, but Medicare and Medicaid as well.
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Finally, Multiple Sclerosis therapies are unique in that increase in competition among MS
medications has led to an increase rather than a decrease in the cost of treatment. With
their various challenges, each case has shown the possibility for different policy
solutions. In reviewing possible policy interventions, I found very little evidence that any
government or private regulation of drug prices would have a negative effect on quality
of care or the price of pharmaceuticals. While it is difficult if not impossible to predict
what the exact outcome of any given policy would be, the risks of further regulating the
pharmaceutical industry are not high. On the other hand, the costs to the health of
patients and the bank accounts of stakeholders are already great, and will only increase if
no intervention is taken. Unfortunately, many of the steps that I will suggest require a
significant amount of political will that would be difficult to muster even in the most
effective of political climates, but certainly will be even more difficult under the current
anti-regulatory administration. However, while many of the government solutions will
not be possible until a shift in political priorities takes place, there are private and
individual steps that can be taken to limit the negative effects of rising prices. Public
pressure and outrage have led to companies lowering prices or introducing generics, and
the informed decisions of healthcare providers like doctors and hospitals to choose more
cost effective options have also made an impact on drug expenditure. While there are
many challenges to achieving equitable access to drugs, there are a myriad of solutions.
This variety can be daunting, and it is hard to say what the most effective solutions will
be, but not knowing which path to choose should not stop us from moving forward to
address the unaffordable cost of pharmaceuticals in the United States.
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Chapter 1: Case Study on EpiPen Prices
In 2015, 3.6 million Americans were prescribed EpiPen to assist in medical
emergencies caused by contact with an allergen29. Unfortunately, due to high costs,
many Americans have to make difficult decisions about whether they can afford the life
saving drug. EpiPen is an auto-injector, which safely delivers a measured dose of
epinephrine into the muscle tissue of an individual experiencing symptoms of
anaphylactic shock. While epinephrine (also known as adrenaline) has been used to treat
anaphylaxis long before EpiPen, auto-injectors have become the safest and quickest way
to deliver epinephrine, and are easy enough to use that patients and bystanders can inject
the drug themselves30. This was an important development in the treatment of severe
allergies because, in cases of anaphylaxis, speedy delivery of epinephrine can save lives,
and in many cases there is not enough time to wait for a health care professional. While
neither the drug itself nor the injection technologies are new, auto-injectors are so
essential to those living with severe allergies, that EpiPen (which has a near monopoly on
the auto-injector industry) has been able to steadily raise prices over the last 10 years
without raising much concern31.
Since 2007 when Mylan, a company that mostly produces generic drugs,
purchased EpiPen, the cost has been rising steadily by about 20% per year. In 2015, the
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price spiked to $600 for a set of two32. While the price paid by individuals varies based
on their health plan, the burden to the healthcare system as a whole is considerable.
Between 2007 and 2014 average out of pocket spending for patients on EpiPen has
increased from $34 to $75 with 18% of patients paying over $100 and 5% paying over
$200 out of pocket33. This is a significant burden for patients to bear, and one which is
magnified when you consider than many patients may elect to buy multiple EpiPens to
keep in the home, car, work/school, and bag, and magnified again because the drug
expires after 12 months, requiring that the drug be replaced annually. Even if an allergy
patient has a great health plan with minimal co-pays, the $600 price tag is significant for
insurers and can contribute to the existing problem of insurance premium increases.
Furthermore, many of the buyers of EpiPens are government insurers like Medicare &
Medicaid, or other tax funded institutions like schools and emergency services. Overall,
whether you have an allergy or not, everyone is helping to pay for the rising costs of
EpiPens.
This latest price increase has led many to question what the reason could be for a
500% price increase over 10 years, when few improvements have been made to the autoinjectors, and when the demand seems to be ever-expanding. While Mylan has been very
secretive about their contracts with their manufacturers and distributors, and unwilling to
give a complete breakdown of their expenses, they have suggested that improvements
like a retractable needle and better grip have resulted in a significant capital investment in
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the injector. Critics wonder if these costs were truly high enough to require such extreme
price hikes, and furthermore, if the changes were a significant enough improvement to
make the increased cost worth it for patients. Some critics believe that the only real
capital investments Mylan has made in EpiPen are their advertising and lobbying
efforts34. Without any internal documents or data from Mylan outlining why the price
increases are necessary, it is hard to believe that what seem like minimal changes could
cause a 500% price increase over 9 years.
Mylan CEO, Heather Bresch, was called by Congress to testify to the EpiPen
price hikes, but in her testimony, Bresch was not very forthcoming about the cost of
EpiPen. She has stated that she cannot disclose the details of Mylan’s contracts with
manufacturers and distributors due to confidentiality agreements. While confidentiality
agreements are common among business partners, when there is such a public risk
associated with rising healthcare costs it seems that more transparency might be
necessary. Bresch continues to play her cards close to her vest, but has made claims that
it costs about $69 to make 2 EpiPens. Independent estimates have produced slightly
different findings; one study concluded that one EpiPen likely only cost $30 to make, or
$60 for the pack of 235. While this difference is not huge, the difference between both
estimates and the $600 price tag certainly is.
Besides the mystery around the true cost of EpiPen, there is also some
controversy over how much Mylan makes off each injector. Bresch has stated that the

34
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$300 rebates they give to insurance companies cut into their profits significantly and that
after rebates and fees Mylan only make $274 per pack36. She further states that other
unnamed fees bring the profits down to about $100 per pack ($160 pre-tax)37. Without a
rigorous account of Mylan’s expenses and costs, it is hard to know whether we can trust
this account. Ronny Gal, a pharmaceutical industry analyst at the investment firm
Sanford Bernstein, says Mylan may make a 40 percent profit margin on the EpiPen, and
that is a conservative estimate38. Critics might claim that demanding a 40% profit margin
off a ubiquitous but life saving drug is highway robbery, especially when one considers
that the 40% profit is likely what is made after the maximum number of rebates and
discounts are offered, and there are likely many EpiPens sold where the profit is far more
than 40%.
EpiPen is not the only drug that has steadily or suddenly increased its prices in the
last few years, but many factors make it an interesting case study in the ethics of drug
pricing. In order to evaluate the ethics of EpiPen’s price, we must compare it to the
framework we have established. In order for a $600 price to be justified, EpiPen must be
a quality drug that is both equitably and fairly accessible. Ethical problems involved in
the EpiPen controversy include questions about the justness of patent law, the use of
marketing and lobbying by “big pharma”, the secrecy with which it operates, the
relationship between drug companies and insurers, and their proposed release of a generic
version of their own product. EpiPen is a safe and effective drug, but is hardly a recent
innovation; yet it remains under patent protection and consumes a 93% market share in
36
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auto-injectors39. Innovation is rewarded and protected by patents, which offer market
exclusivity for a limited period, so investigating the quality, and accessibility of a drug
requires an evaluation of patent protection. First, the market exclusivity offered by
patents allows companies to charge whatever they please with little ability for patients,
insurers or the government to contribute to the determination of a good price. Second,
patents allow companies to sue competitors who attempt to introduce competing drugs on
the basis of patent infringement, and even if the competitor would or could win the
challenge the expense and delay allows the first company to maintain their exclusivity40.
Third, in the case of EpiPen, which is a medical device, not a drug, there are concerns
that it is not really worthy of continued patent protection. Fourth and finally, the
argument for patents is that they encourage innovation and allow companies to recoup the
losses they sustain during drug development, but there is an argument to be made that this
system is not working out as intended and that the current patent system is actually
hindering innovation.
Critics have accused Mylan of taking advantage of the limited competition in the
market for epinephrine auto-injectors by raising prices before their patent expires and
generics begin to compete. EpiPen will be under patent protection until 2025, meaning no
other company can replicate its design until then41. Furthermore, any company that
attempts to patent a new design could face litigation from Mylan if they believe the new
product too closely resembles theirs. This has led to EpiPen taking up a 93% market
39
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share42. This near monopoly is made possible by the patent protections that the US
government offers Mylan and other drug companies. The idea behind these temporary
monopolies is to allow drug companies to make up for capital losses incurred in the
research and development of new drugs, and to protect intellectual property and
encourage innovation. Most companies, including Mylan, argue that while their prices
are often high, they provide great value, and customers are willing to pay a lot for that
value. In an August 2016 interview, Martin Shkreli (also known as Pharma Bro) actually
argued that the $600 price tag on EpiPen is a great value for both patients and insurers
because of the life-saving and potential cost saving affects of the drug43. While it is true
that EpiPen can save lives and limit some of the most serious symptoms of anaphylactic
shock, most cases where an EpiPen is used also require a hospital visit and even an
ambulance ride, which possibly limits the effectiveness of down-the-line cost savings as
an argument for the high price tag. However, even if we were to acknowledge that it is a
drug with life-saving and cost-saving capability, it must also be acknowledged that many
people cannot afford to pay $600 a year for EpiPens, so whether the responsibility lies
with Mylan to lower costs or with insurers to improve benefits, the problem remains that
individuals cannot afford the drug.
Besides the value of their products, companies often argue that while patents are
what allow them to have temporary monopolies at all, the process for obtaining market
access and exclusivity are also to blame for the high prices. Drug companies might
argue that the reason they must charge so much and increase their prices so often is that
42
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the window of exclusivity they have is too short, and they can’t make a significant
enough profit in that time to satisfy their shareholders if they charge a price that
consumers would consider fair. Currently, patents last twenty years and take effect as
soon as the drug is invented44. This seems like a long time, but the FDA approval
process is also very long, often eight and sometimes 12 years, and during that time the
exclusivity clock winds down while the company sees no profits. This would be
understandably frustrating as an executive of a pharmaceutical company and may have
trickle down effects that limit investor confidence in drug research and thus limit
innovation. But does it justify the price spikes that patients endure? While EpiPen is a
quality drug in its safety and effectiveness, it is unaffordable for many Americans, and
this is unjustifiable if the high price is not a necessary cost of ensuring quality. EpiPen
has had patent protection for a long time and will continue to have it till 2025; it has long
since paid for itself and any losses incurred during its development, and yet prices remain
high and Mylan’s profits continue to grow. While there may be an argument that high
prices are necessary to recoup losses, they cannot be justified indefinitely, nor can price
increases be justified once profits exceed the initial loss. Therefore, it seems that the
price of EpiPen is unjustifiable and patent protection is playing a part in allowing the
unjustified prices to continue.
However sympathetic one might be to the “plight” drug companies face in waiting
for approval from the FDA, one could counter that not all products deserve the
exclusivity they are granted, and furthermore that drug companies use very shady
practices to maintain their exclusivity. In the case of EpiPen, the product that is licensed
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is not epinephrine but the auto-injector. There are several factors that can call into
question whether EpiPen deserves the protection it has. To start, the patent for EpiPen is
for the design of the auto-injector and for the stabilized epinephrine solution. The
injector design, while technically unique, is not completely novel; it was based on a
1970s design for an auto-injector that is used by the military to deliver anti-nerve gas
serums to soldiers affected by chemical weapons45. The company that still manufacturers
those injectors is contracted by Mylan to manufacture the EpiPen. So at the time of its
creation the EpiPen was no more innovative than some of the competing injectors that
have been prevented from reaching the market today. The fact that the EpiPen is
primarily a medical device, not a drug, is significant because it is actually more difficult
to improve upon or redesign without appearing to be stealing designs. If it were just a
drug, than one could prove its uniqueness by the chemical formula, but devices are much
harder to prove to be novel. This makes introducing competition to the auto-injector
market more difficult and actually stifles innovation.
There may be some problems in determining what novelty in a medical device or
drug means, but there are really no restrictions on the ability of drug companies to sue
companies that attempt to patent or gain market access for competing products. While
drug companies claim that they deserve market exclusivity because of their innovation
and the value of their products, and while they accuse the process of getting FDA
approval to be too long and costly, they spend their money and the taxpayer’s money on
long legal battles to prevent innovation and competition from other companies. While
companies need to be able to defend their intellectual property, there must be more
intervention on the part of the government to prevent trivial lawsuits. If companies could
45
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just copy old drugs and products and sell them, that would set a dangerous precedent and
could easily harm the pharmaceutical industry and its ability to draw investors in
innovation. However, trivial suits set the same dangerous precedent; they make it
impossible for viable competitors to enter the market because any new drug, even if it is
truly novel, could face a legal challenge if it treats the same condition as another drug.
Currently, even if a suit fails and the new drug is determined to be novel, there is no legal
or financial consequence to the company that challenges the new drug, except the sunken
costs of the suit, which may be worth it to the company if it has delayed the new drug
entering the market46. Mylan has prevented other auto-injectors from entering the market
through such lawsuits, and while it is difficult to say whether they were right about their
claims of copyright infringement, the effect has been that there is no competition for
EpiPen and they can set their own prices47.
I have described many problems with the patent system, both in the eyes of drug
companies and on behalf of consumers. Essentially, drug companies argue that they need
longer lasting patents in order to make enough off their drugs to recoup losses from
development and satisfy shareholders. These points are unconvincing for a lot of
reasons. First, the global pharmaceutical market is worth $300billion, so companies make
enormous profits and clearly are creating returns for shareholders48. Second, it is hard to
see a direct connection between increasing profits and increasing innovation, the most
profitable drug on the market is Lipitor, which is one of many cholesterol-lowering drugs
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and has not been proven more effective than any of the others49. Yet, while the
connection between profits and innovation is dubious, we allow drug companies to set
their own prices unchecked for the duration of their patent life. Furthermore, profits and
private investors are not the only ones sponsoring pharmaceutical research, the Federal
Government provides $32billion annually to fund medical research50. It seems counterintuitive that the people should fund innovation, then be asked to pay high prices in order
to pay back investors. We all have an interest in seeing innovative drugs developed, and
it is great that there is both private and public investment in those innovations. But it
seems that if the government is such a large investor, they should be seeing returns on
those investments, either in the form of lower prices or dividends on profits.
An upshot of market exclusivity is price setting, which leads to price
discrimination, meaning that while they have one list price, they can provide different
discounts or rebates to different customers. By practicing price discrimination companies
are able to charge high prices to those who can afford it, or those who are unable to
bargain (Medicare) without loosing access to markets where customers cannot afford or
won’t pay such high prices. This occurs on an international level with drug companies,
including Mylan, charging different prices in different countries, and this practice has led
to the United States paying more for drugs than any other country in the world. But this
price discrimination also occurs within the United States, because companies like Mylan
negotiate with each buyer separately and can provide different sized rebates to each
insurer. Furthermore, while the rebates they provide may not be enough to allow every
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patient to access the drug, they can still provide individual discounts to patients based on
income. While providing discounts to poor patients should be a sign of positive price
discrimination that improves access, in general, the process of price discrimination means
that companies can extract every available penny from the healthcare industry.
In order for price discrimination to be justifiable in the pharmaceutical industry, it
must enhance rather than hinder equity of access. Thus, price discrimination should not
just allow private groups to bargain for lower prices, but should actively seek to ensure
that the most vulnerable pay the least for drugs. What is notable about price
discrimination in the United States is that while those without insurance may receive
discounts from manufacturers, Medicare and Medicaid, which insure the elderly and the
poor respectively, often end up receiving the worst deals in price negotiation. In the case
of Medicare, this is because they are unable to bargain for lower prices at all, and in
Medicaid because it is managed differently in each state and lacks strong support from
the federal government. Despite the difficulties in negotiating lower prices for Medicare
and Medicaid, it would seem that there is a positive duty on behalf of manufacturers to
ensure that these programs have access to a low price for drugs, at least as low (if not
lower) than the prices negotiated by private insurers. But what happens all too often is
that these government programs, which represent the most vulnerable segments of our
population, pay the highest prices for drugs. Prices are not justifiable if their price
discrimination disadvantages the vulnerable, and when this is the case the positive
responsibility to take action lies with the drug company to use negotiation tactics that are
more equitable.
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While the price discrimination practiced by drug companies is unjustifiable,
companies would naturally resist the idea of price regulation, perhaps arguing that the
forces effecting drug prices are varied, complex and dynamic, and setting a price cap
would not allow the industry to be responsive to changes. It seems fair to say that there
are factors that lead to price fluctuation, but there is no evidence that the dramatic price
increases we have seen across the medical industry due to “changing market forces.”
Rather it seems that the dramatic increases are due to the industry being allowed to
regulate itself. In the case of EpiPen the only fluctuation that seems to appear in their
costs is the dramatic increase in advertising, lobbying and information campaigns.
Furthermore, it may be that Mylan purposefully chose the beginning of the school year as
the time to raise prices as both students and schools were stocking up for the year. This
is especially problematic when we consider the extensive effort Mylan made to lobby the
federal government to encourage schools to stock EpiPens.
Mylan has recently succeeded in getting a federal law passed to provide funding
for schools to stock EpiPens, as well several state laws that mandate EpiPens be carried
in schools51. In theory this would be a noble goal that expands access to a life-saving
drug, but in practice it is a means Mylan secured a legal mandate for more customers to
purchase their product before jacking their prices up further. In a way, Mylan has pulled
the wool over the eyes of legislators, lobbying them to mandate that the product then
raising the prices once the schools, which are already underfunded in most districts,
cannot opt out. Furthermore, Congress passed the law with a certain budget in mind, and
that budget will not stretch as far now that the prices have increased. What adds insult to
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injury is that Mylan cites their lobbying efforts as justification for their price increases 52.
Mylan executives do not deny that their lobbying efforts were a major expense and may
be a part of the price increase, but they do not seem to see the worry that crops up when a
private corporation convinces the government to encourage or even require the purchase
of their product and then increases the price. Mylan might argue that they provided a
public service in expanding access, and relieved some of the burden on families to have
multiple pens for their child, because at least the school would always have one. But by
raising their prices they limit the good this program could have done, by increasing the
burden for already strained school budgets and increasing the burden for families, who
still need to buy a pen for their child for when they aren’t at school. To compensate for
that, Mylan gave out thousands of free EpiPens to schools after the new law was passed,
in response to the high prices. But providing some EpiPens for free does not make up for
the damage done by the extreme costs to the school and health systems caused by their
price increases.
Perhaps the public should be expected to take on all the costs of bringing EpiPens
into schools because it is a public good that the government should have seen to without
Mylan’s lobbying. After all, Mylan wasn't the only group advocating for more awareness
of anaphylaxis and greater availability of EpiPen. The Food Allergy Research and
Education group (FARE) also supports greater availability of EpiPen, but Mylan is a
significant donor to FARE, so can the public trust their recommendations?53 Overall,
giving out EpiPens to schools and providing savings cards to low and middle/low income
Americans do not necessarily improve access, because they may exclude as many people
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as they include, and the measures only help if they offer them year after year, and if they
don’t continue to raise their prices. Mylan might say that the $600 price is “worth it” to
consumers, insurers and taxpayers, but just because a drug is “worth” a certain price,
doesn't mean that that price is fair, especially when those prices are coming out of patient
pockets. Many people may say that EpiPen is “worth” the $600, but if they don’t have
$600 its worth doesn’t matter because they simply can’t afford it. Mylan’s spending on
advertising, lobbying and even their “charitable” gifts to non-profits, call into question
whether consumers are being given the opportunity to make informed decisions about
their health. If government decisions are being influenced by lobbying, and public
opinion is being swayed by advertising and EpiPen subsidized education campaigns, then
it is difficult to say whether consumers are able to make informed choices. Add to that
the opacity of Mylan’s communications about their costs, and the public has virtually no
trustworthy information about EpiPen.
In addition to their suspicious practices in lobbying the government, Mylan and
other drug companies have participated in creative but questionable bargaining practices
with insurance companies. Mylan offers $300 rebates to many insurance companies who
include EpiPen in their formularies, which raises questions about whether the insurers
have any interest in lowering prices, and about why the prices would be so high if the
private insurers all pay less54. The answer may be that because Medicare cannot bargain
for lower prices, taxpayers and the elderly may be paying the $600 sticker price when no
one else is. These rebates are suspicious because they suggest that there really is no
reason for the $600 price tag, except for the fact that Mylan has nothing stopping it from
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charging as much as they want, since there is a costumer (Medicare) who will have to pay
whatever price they are offered. What is further disturbing and implicates insurers in
rising costs, is that despite the rebates given to the insurers, many patients still have high
out of pocket costs, suggesting that insurers are not passing their savings on to customers.
These deals between insurers and drug companies are also problematic in the exclusivity
of the deals that are made. If these bargains were not struck, one could argue that
EpiPen’s competitors may have had an easier time gaining market share. As it stands, if
an insurer wishes to pay less than $600 they most likely have to agree not to cover non
EpiPen auto-injectors55. It seems that there should be a shared sense of responsibility for
setting fair prices, and insurance companies should allow their customers to retain their
choice of drugs and treatments, especially where cost differences exist.
Many problems associated with drug pricing and drug company practices,
including Mylan, are difficult to really parse out because of the secrecy under which the
industry operates. Even when called in to testify for Congress, Heather Bresch refused to
give the full picture of the costs of manufacturing and selling EpiPen, or the deals made
with insurers. This cloud of secrecy makes it very difficult to fully understand the true
reasons for rising drug costs and thus makes it difficult to determine for certain whether
prices are ethically justifiable. This opacity must be cleared if we are to get an accurate
picture of drug pricing ethics. Furthermore, while the opacity makes it difficult to
understand the drug pricing landscape, it also suggests fishy practices on the part of
pharmaceutical companies. The lack of information is a problem because it hinders our
ability to answer some of our ethical questions about the fairness of prices being set, but
it is also an ethical problem in itself. We do not only want to know about the workings of
55
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Mylan in order to know whether they are up to no good, we also just have a right to know
what we are paying for, and to make informed decisions about all our purchases. This
right to make informed decisions is even more important in health industries, because of
the high stakes for patients and high costs to consumers.
All of these ethical questions have been raised since the last price increase of
EpiPen, and in response to the public outcry about the unreasonable cost Mylan has
decided to release a generic version of the EpiPen. While it is certainly a positive step
that the company felt the need to take steps in response to the public outcry, their
decision to release a generic to compete with their own product is an interesting one, and
may have further effects on price discrimination. Once they release the generic, which
will be completely identical to EpiPen except for the label, Mylan plans to list it at $300
for a pack of two. But the question is why not just lower the price of the brand name to
$300, especially since that is already the price most insurers pay after rebates? There has
been some speculation that releasing a generic will actually have very little impact on the
cost of EpiPens, because insurance companies will continue to cover the brand name with
the old rebates, or will purchase the generic for the same price56. The offer of a generic
may have an effect on Medicare because their lack of bargaining power may mean that
they have paid the most for brand name EpiPens, but again because of the secrecy of the
industry we do not know who pays what.
Throughout this case study, several key questions arose that will relate to future
case studies, and to the overall goal of determining whether the prices we pay for
pharmaceuticals are justified. Mylan is certainly not the only company to take advantage
56

Garde, Damian. "How the generic EpiPen can actually boost profits for Mylan." STAT News.
August 29, 2016. Accessed October 15, 2016. https://www.statnews.com/2016/08/29/generic-epipenmylan-profit/.

28

of market exclusivity, and it may not be right to place blame on them for trying to make a
profit when that is their goal as a private company. However, the way in which Mylan
and other companies use market exclusivity is wrong, and we should not allow them to
set their own prices without the regulation of government or competition. This seems at
least in part to be because of a lack of reciprocity between the pharmaceutical companies
and the public, the public provides patent protection so the pharmaceutical companies
should be paying them back by not charging exorbitant rates, or at least not by wasting
public resources with long legal battles to extend exclusivity. Another issue of
reciprocity seems to be in the issue of research and development, prevailing studies seem
to indicate that drug companies spend much more on money on advertising then research
(this is certainly the case with EpiPen), while the NIH takes on the risk of investing
billions in innovation. Without diving into the complex slew of ethical issues associated
with drug marketing, it is clear in the case of EpiPen, the public is being charged
repeatedly for the same product: first through the taxpayer dollars funding innovation,
Medicare and Medicaid, second through health insurance premiums and third at the
pharmacy counter. In order for the price of EpiPen to be justified, it must match the
criteria established; it much be a quality product available to all at prices they can afford
that allows for both consumer choice and corporate profit. EpiPen is a quality product
that saves lives, but its price makes it unaffordable to many Americans and places as high
burden on individuals and insurers (particularly the most vulnerable). Furthermore, the
high prices are not necessary for recouping any losses sustained in improving the quality
of EpiPen, because the prices have been going up even when no changes had been made.
Additionally, the secrecy under which Mylan operates and their marketing and lobbying
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efforts have limited consumer choice and obstructed the right of patients and consumers
to know what they are paying for. While the prices charged by Mylan are not justifiable,
there is a shared responsibility for bringing down costs. Mylan certainly takes the blame
for taking advantage of market exclusivity to set high prices, practice unfair price
discrimination and hiding information from the public, but private insurers, the
government, and individuals also must accept responsibility for bringing down costs.
After reviewing all of the case studies, I will show what policies can be implemented by
all of these groups to lower costs.
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Chapter 2: Case Study on Hepatitis C Treatment Costs
Hepatitis is a tricky disease to nail down, some estimate that between three and
five million Americans are infected, but only half know it. This is because Hepatitis can
lay dormant in the body for decades, or present itself with flu-like symptoms early on.
Around a quarter of those affected by the disease have it for only a short time because
their bodies fight it off on their own. Most people infected with Hepatits, about 2.7
million Americans, develop chronic Hepatitis (Hepatitis C or Hep C). Hepatitis C has a
spectrum of severity within itself as well as a six distinct virus strains. Chronic Hepatitis
can also start with flu symptoms, but down the line can lead to chronic liver disease,
cirrhosis of the liver, and liver cancer. Hepatitis is a blood borne illness and most patients
develop it through injected drug use, or from blood transfusions received prior to 1992 (at
which time a screening test was developed to detect Hepatitis) 57. The connection
between Hepatitis C and injected drug use creates many problems for treatment, because
patients may be disconnected from health care, they may face stigma in trying to access
care, and if they are uninsured they may not be able to afford it. Furthermore, there are
some concerns that even when Hepatitis patients who use drugs receive treatment they do
not follow through.
Treating Hepatitis C has always been costly, even before anti-viral treatments
were available, the cost of treating the long-term liver damage can be millions of dollars
for just one patient. Early anti-viral drugs attempted to curb these costs and the harm
done by the disease by attacking the virus before it can cause too much damage. These
early anti-viral medications were administered intravenously in hospitals, so it was very
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difficult for patients to keep up with the treatment. Furthermore, they were not very
effective, safe nor cheap. Since 1991, when the FDA approved the first Hepatitis C
treatment, advances have slowly been made to improve the quality of life and health
outcomes for Hep C patients. At the start, even with treatment there was very little
chance of clearing the infection. Most treatments were administered intravenously in
hospitals and were prescribed only to those who had already developed liver disease.
The necessity of getting to a hospital and possibly remaining there for long stretches of
time was a significant burden for patients, especially those who suffered from drug
addiction or were uninsured. Treatments before 2013 were not recommended for patients
suffering from HIV co-infection or liver cancer nor were they effective across the
spectrum of Hepatitis C genotypes.58
Since 2013, treatments have become safer, more effective and more widely
usable—across multiple Hepatitis genotypes, in patients with co-infections like HIV and
during many stages of disease progression. In 2013 the first oral medications for Hep C Sovaldi and Olysio - were approved, making treatment easier for patients to obtain and
keep up with; however these treatments were still recommended in conjunction with
intravenous, hospital-administered medication. While these medications made dramatic
steps in efficacy and in the spectrum of patients that could be treated, fully outpatient care
was still out of reach for another year. In 2014, Harvoni and Viekira Pak were approved
by the FDA as fully oral regimes; however they are only shown effective in patients with
Hepatitis C genotype 1 and not for patients with co-infections. In the next year other oral
treatments were introduced to treat Hepatitis C genotypes 3 and 4, but in 2016 the first
drugs designed to treat the full spectrum of Hepatitis genotypes are approved. These
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drugs - Zepatier and Epclusa - are all oral, single tablet regimens, which after 12 weeks
see 94-100 percent of patients’ virus free. For patients fighting Hepatitis, these drugs
could be life-saving and come with both more guarantee of success and less commitment
from the patient59. However, while these new drugs truly solve some of the pressing
issues of Hepatitis C treatment, and reduce some of the costs associated with hospital
administered treatment, the cost of these drugs is still very high and is causing major
problems for both individuals and providers.
With the greater efficacy, broader use and ease of new treatments comes higher
demand. More and more people with Hepatitis C are looking for a cure, but due to the
high cost of the treatment providers are worried about the increased costs. Since 2014,
new Hepatitis C medications have led to a 13.1% increase in prescription drug spending
nationally and the Center for Medicare and Medicaid services estimates that the demand
for and cost of Hep C drugs will lead to an additional $65 billion in spending over the
next 5 years in comparison with previous treatments60. These costs are staggering, but
are not surprising given the $54,000-$94,000 price tags. It is certainly shocking when
Zepatier can advertise itself as a bargain at $54,000 for a 12-week course because their
biggest competitor Epclusa costs $74,000. To be fair, compared to the costs the last
generation of Hepatitis C medications (Harvoni costs an average of $94,000 per course),
the newer generation does save money61. This is further true when we factor in the cost
saving associated with reduced rates of liver disease (a liver transplant can cost $700,000
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for the surgery alone)62, but in the short term costs are going way up because of the
increased demand for the improved drugs.
The increase in demand is significant and has many causes; the newer drugs are
more effective, have fewer immediate side effects and are less cumbersome as they
generally consist of a once daily pill. Furthermore, previous generations of treatments
have been unavailable and unusable for broad spectrums of the Hepatitis C infected
populations. Previous generations of drugs were only effective on individuals at specific
stages of liver disease caused by Hepatitis C, and not available to those with HIV coinfection. Because the newer drugs are usable by broader spectrums of the Hep C
positive population, the demand, and thus cost, is going up. This has caused rationing on
the part of insurers in order to limit the amount of patients eligible for the new drugs.
Many insurers have decided that in order to receive these drugs a patient must have liver
disease diagnosed by biopsy63. This means that many patients who are Hep C positive
are not eligible for treatment until they are experiencing liver disease which may have
painful symptoms and which must be diagnosed through a somewhat dangerous
procedure. Some exceptions to these rationing rules can be made in cases where coinfection can increase the risks associated with liver disease or biopsy, such as kidney
disease or HIV, but overall it seems that there are some serious problems caused by the
costs of Hep C medications.
The prohibitive costs of Hepatitis C drugs are problematic for one major reason; it
forces a decision for healthcare providers in which they must choose between the prime

62

Ibid.
Freyer, Felice J. "Hepatitis C Drug Costs Leave Many without Care." The Boston Globe
(Boston, MA), April 9, 2016. Accessed November 1, 2016. http://www.highbeam.com/doc/1P239499903.html?refid=easy_hf.
63

34

objective of doctors to improve health and prevent illness, and the necessity of having a
sustainable healthcare system that can continue to treat and support patients for years to
come. The position that the prices of Hepatitis C drugs put us in is one where we must
decide to prevent and fight liver disease by attacking its cause—Hepatitis C—but in
doing so bankrupt our healthcare system. This is an impossible situation because
whatever the choice, the outcome means that patients will not receive treatment, whether
now or in the future.
While insurance companies and doctors state the need to lower the costs to treat a
wider range of patients, drug companies state that the prices they have set for their
products are fair. Many of their reasons are similar to those we have heard from Mylan
and other drug companies, which is that the innovation of their company comes at a
price. This argument is more compelling in this case than in Mylan’s, because we can
see from the progression of Hepatitis C treatments that these newer drugs are better than
what has come before, and the research needed to develop them may well have been
expensive. On their last drug to treat Hepatitis C – Harvoni—which costs over $1000 per
pill, Gilead industries made $18 billion in 2015 alone, and on their new drug, Epclusa,
which costs around $900 per pill they could stand to make even more because of
increased demand64. Whatever the losses sustained in research or from lower sales of
Harvoni and other older drugs, Gilead still stands to increase revenue by $1.8 billion this
year.65 There is no doubt that they will make money from Epclusa nor that Epclusa is a
better treatment and will help more people than previous generations. But how much
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profit is necessary to stimulate innovation? A company would never invest in drugs that
they couldn't profit from or would lose money on, and we want to invest in innovation
and encourage companies to develop new drugs. But the cost of treating Hepatitis C
could bankrupt our public healthcare systems. Part of the reason why costs to our overall
health system are going up even though Epclusa and its competitors cost less than the last
generation of drugs is that they are effective in more patients, so demand has gone up.
But because the drugs are priced so high, insurers are limiting who can access them, so
one might wonder whether it is in Gilead’s or the public’s interest to maintain the high
prices. Setting a lower price could mean that all 2.7 million people effected by Hep C in
the US have access to treatment, and Gilead could still make a huge profit. Even if they
couldn’t make more money, or even the same amount of money by making it available to
more people, they would certainly still be making a great deal of money. While Gilead is
certainly benefiting form the price they set, many Americans are losing out, and many
more are becoming affected, as those with the disease pass it on to others. The incredible
possibility created by being able to cure Hep C, is that we cannot only help those already
effected, but can help stop the spread of the disease. Currently a major hurdle to fighting
Hep C, is that patients continue to practice high-risk behaviors like drug use, and pass on
the disease to others. But being able to cure Hep C is almost as good as a vaccine in that
it stops patients from being able to infect others. The truly troubling question this raises
is whether it is in Gilead’s interest to cure everyone of Hep C, because it would mean
they are not guaranteed a large customer base in the future. This further raises the
question of whether Gilead may be intentionally making their drug unaffordable to ensure
that many people remain in need of care.
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The problem with Hepatitis C is that its primary patient base is drug users, which
means that before there were curative treatments that are relatively easy to follow through
with, the amount of patients seeking treatment for their Hep C was small. Many drug
users were unwilling or unable to be in the hospital for long-term treatment and were
unlikely to be aware that they carried the virus till late in the stages of cirrhosis. With
expansion of health insurance and healthcare, and with more ease of treatment there is a
far greater demand for treatment, but unfortunately the prejudice against injecting drug
users does not make them sympathetic victims of healthcare rationing. When a child is at
risk of death from anaphylactic shock, there is very understandable public outcry, but
when a drug user or former drug user develops cirrhosis, they are seen to have brought
their troubles on themselves. Thus there is some concern that drug companies and
insurers may not see the harm in rationing Hep C drugs, or waiting until patients get sick
before they provide cures, because the most needy patients in Hep C cases are those who
are seen as untrustworthy and likely to relapse. So even if companies like Gilead are
intentionally ensuring that many people remain sick, public outrage is not as likely if the
victims are unsympathetic.
This problem is further complicated by the fact that most of these high-risk
patients will get their insurance through Medicaid and Medicare, which are in the most
precarious financial position and have the least ability to bargain with drug companies
over cost. Hepatitis C is likely to cost Medicaid and Medicare 10’s of billions of dollars
in the next five years, and the only possible means to avoiding financial disaster seems to
be denying care, which is unconscionable, and negotiating lower prices, which is
currently illegal. While it is certainly true that curing more people of Hep C will reduce
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the amount of liver transplants and hospital stays that are associated cirrhosis caused by
Hep C, those savings won’t be seen for years. For now, the insurance industry is dealing
with the costs of those who developed cirrhosis before a cure was available, those who
are experiencing symptoms of cirrhosis while they wait for their disease to develop to the
point that they qualify for the cure, and the cost of the cure. So in reality, costs are
getting much higher and will remain high so long as more people develop Hep C than
there is money to cure them.
New Hepatitis treatments align with the goal of improving health, they are
certainly innovative, and while not without their share of serious side effects, they
improve health outcomes for patients and can generally be regarded as both safe and
effective. Furthermore, there were certainly high costs incurred to achieve this
breakthrough and so there may be a justification for high prices. One may be
sympathetic with the argument that while prices are high they reflect future savings. Still,
one would hope that the aim of the health industry in making technological advances is to
improve the quality of life for patients and reduce the toll of illness on our patients and
our wallets. So perhaps cost savings are not as relevant as the life saving benefits of the
drug, and justification for high costs should come from the value of the drug and the cost
of research, not the cost savings. In my view, citing down-the-line savings for health
insurers is a type of veiled reference to down-the-line losses for drug companies. We
should not factor in future losses to current prices, only past losses. The projections for
Gilead’s revenue show an increase of over a billion dollars in profit within the first year
of Epclusa reaching patients. This shows that even accounting for investment in its
research and losses on increasingly obsolete treatments, Gilead is making plenty of
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money off their new product. But in making these billions, Gilead is denying access to
millions of Americans and putting our entire healthcare system in jeopardy. By making
their product inaccessible, Gilead is forcing patients to suffer through liver disease when
it is no longer necessary for them to do so. This high human cost can only be justified if
it is necessary to pay for the development of the drug, or necessary to keep them in
business. This is not the case for Gilead; their high profits in the first year of selling their
product even as huge portions of customers are excluded, show that there is room in their
bottom line to negotiate lower prices. With 2.7 million possible customers in the US
alone, there is a huge margin for profit, and it is not necessary to set such high prices.
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Chapter 3: Case Study On the Cost of Treatment of Multiple Sclerosis
Multiple Sclerosis, or MS, is a relatively rare and potentially debilitating disease
of the central nervous system. MS is generally developed by patients between the ages of
20 and 50 with about 200,000 patients developing the disease per year in the US. While
the exact cause is unknown, it is likely caused by a combination of genetic and
environmental risk factors. In cases of Multiple Sclerosis, the patients’ immune system
begins to attack the protective coating around nerve fibers, preventing the patient’s brain
and spinal cord from engaging in proper communication with the rest of the body.
Multiple Sclerosis is a progressive disease, and the deterioration of nerve coating can
spread over time and can also become permanent. The symptoms of MS are wide
ranging from numbness or weakness in one or more limbs to vision problems to tingling
and pain in any part of the body to tremors and loss of motor control66.
Cases of MS fall into a couple different categories, from relapsing-remitting to
primary and secondary-progressive MS. Most people with Multiple Sclerosis have
relapsing-remitting disease courses in which they experience a-symptomatic periods
broken up by relapses that may last days or weeks but which lift partially or completely;
periods of remission may last months or even years. However, 60-70% of people with
relapsing-remitting MS experience a steady progression of their symptoms into
secondary-progressive MS. In these cases patients have an increase in the severity or
frequency of their symptoms, and may or may not experience as many or as lengthy
periods of remission. The final and most rare category of MS is primary-progressive; in
these cases patients experience a steady progression of symptoms from the onset of their
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illness, while this progression may be very slow these patients experience no relapses or
periods of remission67.
While there is still no cure for Multiple Sclerosis, there are two main avenues of
treatment. One means of treatment is to assist in the recovery of patients after MS
relapses or acute symptoms. To treat acute attacks of MS, patients might use steroids to
reduce nerve inflammation or might receive blood plasma exchanges if they have not
responded to steroids. Patients may attempt to relieve and manage symptoms by using
muscle relaxants to alleviate muscle pain and spasms, or may use physical therapy and/or
mobility aids to learn to manage their symptoms and continue on with their lives and jobs
while fighting MS. The other avenue, is to attempt to slow the progression of the disease
and prevent relapses; this form of treatment is expensive and ongoing and will be the
focus of this chapter. There are many treatments available to modify disease progression,
but many of them come with serious side effects and may lose their efficacy requiring
regular evaluation and treatment changes. Disease Modifying Treatments or DMTs were
first introduced in 1993 and at first there were very few options, but now there are about
ten main DMTs prescribed to MS patients68. It should be noted that there is some debate
in the scientific community concerning the efficacy of DMTs for MS69. I will address the
need for more studies on the comparative efficacy of the different treatments, but I will
be giving both companies and patients the benefit of the doubt and will work with the
assumption that these drugs provide value to patients.
The first class of these drugs are beta interferons, which are the most widely
prescribed and are very effective in reducing relapses, but they carry side effects of flu
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symptoms, require injections which may cause negative reactions, can do irreversible
liver damage, and can lose their efficacy after prolonged periods of use. Other first line
medications include: 1) Copaxone, which may stop the patient’s immune system from
attacking the nerve coating but causes injection site reactions, 2) Tecfidera, which is
taken orally but has digestive and immune side effects, and 3) Gilenva, another oral
medication which reduces relapses but also slows the heart rate and causes headaches,
high blood pressure and blurred vision. Aubagio is another oral medication that reduces
relapse rate, but also causes liver damage, hair loss, and can be harmful to a developing
fetus. Tysabri stops immune cells from reaching the spinal cord and brain, but is
generally used as a second line defense after other medications have failed or as a first
line in very severe cases, because blocking immune cells from the spinal cord and brain
can put patients at a high risk of infection. Lemtrada is another aggressive but risky drug,
it can limit potential nerve damage caused by immune cells, but it can also inhibit the
body’s ability to fight infection, and requires several days of hospitalization while the
drug is administered. Finally, Mitoxantrone is another immunosuppressant that is used in
a very limited capacity to treat the most severe and advanced cases of MS, this drug can
damage a patients heart and may contribute to the development of some blood cancers70.
In the last 20 years there has been vast improvement in the number of diseasemodifying therapies available for MS, from one beta-interferon treatment in 1993 to 10
different treatments today. While this has provided more choice to doctors and patients,
and has given them the ability to find the treatment that works best for each patient, there
is still no cure for MS nor is there a drug that consistently or completely stops relapses.
Furthermore the side effects of these drugs run the gamut from irritating to risky to
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potentially fatal. While the symptoms of MS and the side effects of its treatments are
distressing enough, another layer of anxiety is added by the extreme cost of MS diseasemodifying treatments. There is currently no DMT with a sticker price of less than
$50,000 per year, and this is not a one-time cost, patients wishing to limit their relapses
or manage their disease progression need to remain on DMTs for their whole life71.
Very few individuals or insurers pay the full price for these medications, but Medicare
does, and even after negotiations and rebates, the price remains very high for insurers,
patients, and our health care system as a whole. And what is further distressing about the
price of these drugs is that despite the increase in competition, prices have gone up not
down, defying our classical economic expectations and the common fears expressed by
the pharmaceutical industry regarding competition.
In the last three years there have been two major reviews of the cost of Multiple
Sclerosis treatment. In 2013, the Journal of Medical Economics found that the costs of
treating MS had risen from an average of $8,500 per year in 1999 to more than $50,000
per year in 2008. According to this study, the rising costs of DMTs accounted for most
of this increase72. These rising costs pose major problems for patients, doctors and
insurers; rising costs have contributed to increases in premiums for all insured Americans
and these rising costs and premiums have also led to more high deductible plans and high
co-pays. High co-pays and deductibles are particularly problematic for MS patients since
many are unable to work because of their disease. According to Dr. LaRocca, vice
president of healthcare delivery and policy research at the National Multiple Sclerosis
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Society (NMSS), “Over the last few years, the prices of MS disease-modifying drugs
have escalated faster than inflation. Most people with MS are able to cover their
healthcare expenses, but it is challenging and has led many of them to make
compromises, such as skipping doses or taking drug holidays.”73 Skipping doses or taking
smaller doses than prescribed can be very dangerous, especially in MS medications that
have both serious side effects, and serious symptoms when drugs are ineffective; drug
holidays, where patients temporarily stop filling their prescriptions are also very
dangerous and put patients at risk for experiencing disease progression or relapse. These
cost saving measures are not things that any patient should ever have to consider.
Another study, published by the American Academy of Neurology in 2015,
evaluated the effect that new drugs entering the market had on the price of existing drugs
and on the average cost of DMTs. It is a generally accepted theory of classical
economics that as the number of products meeting a certain demand increases, then the
competition for buyers will drive the prices of these products down. This should be
especially true if newer drugs are more effective or more convenient, because older drugs
would need to price themselves lower to compete with the better drugs, or at least this is
what classical economists teach us. However, the results of this study showed something
very different. The first drugs to treat MS came on to the market priced between $8,000
and $12,000 per year, and after 1996 new drugs entering the market had a list price about
25-60% higher than the old medications. This price difference is to be expected, the
newer medications would be offering some new value, for which they would demand a
higher price. What is surprising, however, is large increases in the costs of firstgeneration drugs, but after the approval of the third beta-interferon drug (Rebif) in 2002
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and Natalizumab in 2006, the prices of both old and new drugs began to increase
dramatically. The costs of MS drugs have been increasing far faster than inflation, the
average cost of prescription drugs in general, and even faster than other medication
within the same class (Biologics). If the cost of the first-generation beta-interpherons had
been increasing at the rate of inflation, they would have cost between $12,000 and
$19,000 per year in 2013, but instead they cost $62,000 per year. In 2015 DMTs cost
two to three times more in the US compared to similar countries, and there are now no
DMTs costing less than $50,000 per year (before rebates)74.
It is not just shocking that the cost of first-generations have increased despite
competition, but that the first-generations have raised prices at a higher annual rate than
their competitors, and some of the early drugs actually cost more than newer ones. The
average increase in prescription drug prices in America between 1996 and 2010 was
about 3%-5% annually. During the same period, the average annual price increase of
first generation DMTs is 21%-36%, while the newer oral medications, have increased
prices 8%-17% annually. Currently, the very first MS drug ever introduced, Betaseron
(released 1993), costs $61,000 per year while Extavia (released 2009) costs $51,000 per
year, both of these drugs are beta-interpherons with similar modes of delivery and side
effects. The dramatic increase in first-generation prices seems closely tied with the
introduction of newer drugs, but not because of some increase in manufacturing costs,
otherwise international prices would have risen too75. This suggests that companies
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increased their prices in response to the prices of their competitors. This trend defies the
rules given to us by classical economists. John Tozzi has an interesting analogy for the
problem with these MS drug-pricing schemes. He compares these drugs to iPhones and
asks us to imagine if Apple sold its oldest iPhone alongside each generation of new
iPhone and each time it released a new phone it raised the price of the older generation to
match the price of the new phone76. Obviously that would make no sense, no one would
buy the older phone and they would be forced to abandon the practice. So why is this
working for the manufacturers of MS drugs?
In the 2015 Neurology study, a few different reasons for this extreme increase are
posited. The simplest explanation, in their view, is that the drug companies are just
taking advantage of our flawed system, which puts no limits on the prices of
pharmaceuticals and thus allows companies to steadily increase prices in order to
maximize profits77. Old companies realize that there is a willingness to pay more for
their drugs, and because there is no ability to boycott drugs there is no public or private
sector means of limiting the price increases. Unfortunately the payers most affected by
these increases are Medicare patients, and taxpayers funding Medicare. Medicare is one
of the largest health insurance providers in the United States, but is likely the only one
paying the full sticker price for the horrendously expensive drugs in this country. The
Neurology study admits that the landscape of drug pricing is very complicated and there
are more reasons than just greed leading to high prices; complications caused by patent
monopolies, third party pharmacy benefit managers, and lack of comparative clinical
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studies all led to our current dysfunctional system78. However, there is also very little
transparency in these price setting decisions and that can lead some to some very cynical
speculations, like that these price hikes suggest collusion between drug companies.
While price data may not be enough to prove collusion, the general market trends in the
pharmaceutical industry suggest that companies are not competing on price.
Pharmaceutical industry representatives dispute claims that drug inflation has
been greater than medical inflation overall. However in the case of MS this seems to be
false, as the costs have risen by over 20% annually for first generation drugs compared to
the 3%-5% increase for pharmaceuticals overall79. Another claim is that most of the
price increases on innovative drugs are offset by price reductions in other areas as
generics hit the market, but one could argue that drug companies have been working hard
to prevent generics from accomplishing this balance by preventing them from reaching
the market. They also argue that looking at the list price is not a fair measure, because so
many of the insurers receive rebates or negotiate lower prices, and patients often receive
help from drug companies in managing co-pays when they are prohibitive. However,
while this is true for private insurers, Medicaid and the VA, it is not true for Medicare
and so both Medicare beneficiaries and taxpayers are paying the full list price for MS
drugs. Furthermore, waiting for and depending upon financial assistance from drug
companies is a vary precarious position to be in as a patient and it seems like it would be
much simpler if the drug companies would only charge a fair price for their products.
Dr Kenneth Kaitin, Professor of Medicine at Tufts University has an interesting
take on pharmaceutical pricing that is both skeptical of and sympathetic to drug
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companies. He has a healthy amount of suspicion about the pricing decisions made by
drug companies, because he has never seen any description of their pricing process and
there is currently no requirement or incentive for them to be forthcoming about those
decisions. This lack of transparency allows the companies to drive the narrative about
drug pricing, they can claim that the high costs of research, development and brining
drugs to market all drive up prices. Dr. Kaitin suspects that something else is at work
though, and that is value.
The real factor is value. If you develop a very expensive drug that
few people are interested in, then you’re not going to price it high
because then even fewer people will be interested in it. In that
regard, pharmaceuticals are just like any other commodity, any
other product…If you develop a product that doesn’t cost too
much to manufacture, however if it’s of tremendously high value,
it’s going to be priced very high.
Dr. Kaitin is explaining here that in some ways they are limited by the laws of supply and
demand; they cannot charge the extreme prices they do for MS drugs for products with
very little value. However, because unlike other products, consumers cannot choose to
forgo purchasing a drug, and in some ways may not even be able to go to a competitor for
a drug if that is not covered or if it will not be effective in their case. Dr. Kaitin
emphasized the need for drug companies to have balanced portfolios of drugs, some that
are high earners, like DMTs, so that they can support less profitable drugs and fund
research efforts. While major drug companies may not be doing very innovative research
to find cures in house, they invest heavily in smaller labs, which often go under80.
Despite these defenses of drug companies price setting choices, there seems to be
something particularly disturbing about the trend in Multiple Sclerosis medication
80

Burtchell, Jeri. "Should Multiple Sclerosis Drugs Cost $62,000 a Year?" Healthline. July 19,
2013. Accessed November 01, 2016. http://www.healthline.com/health-news/ms-why-are-ms-drug-pricesso-high-071913#1.

48

pricing. Part of the reason for this concern is the consequences it is already having for
patients and payers, and the fact that there is nothing really stopping the prices from
increasing indefinitely. These price increases are already leading to serious consequences
for patients and insurers. The high prices have caused insurance companies to make
decisions on their formularies based on preferential price negotiations rather than by the
value of the drugs to patients. Furthermore, insurance companies have a tendency to
deny first requests by patients for expensive drugs, causing delays for patients in
accessing care as doctors and patients comply with the multiple approval steps. All
together the high costs of drugs and the responses to them by insurance companies has
added undue burdens to patients already struggling with the stress and complications of
serious diseases. It seems that there are four main ethical problems with the price of
Multiple Sclerosis drugs; 1) the backwards practice of drug companies raising prices to
match competitors, 2) the lack of any cap or end to this inflation, 3) the rebates used to
lower prices for patients and insurance companies rather than actually lowering prices
and 4) the problems with the bargaining power of Medicare and patients.
The pricing of MS medications defies all the rules we are supposed to accept
concerning competition and prices. This poses a very serious objection to the way our
pharmaceutical system works and is concerning for the future of the industry. DMT
prices have shown that there is no invisible hand guiding drug prices and keeping them
affordable, even in cases where there is competition. Each increase in price or
introduction of a new drug has just proven that the willingness to pay for MS drugs is
high, and each increase in price for one drug has encouraged competitors to raise prices.
This is a very problematic system, because while it is true that there is a high willingness
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to pay for these drugs, this willingness is coming from a point of near duress for patients
and providers. Patients and providers are not willing to pay the high prices, they are
forced to pay whatever price the companies decide on because the alternative is MS
attacks, relapses and a steady progression of symptoms.
These price increases seem to show that companies are not setting prices based on
increasing manufacturing costs or other variables. Even if companies are using their
blockbuster or strong revenue producing drugs to pay for research ventures, it does not
follow that these prices are reasonable. It is in the interest of our medical system and of
MS patients themselves for more research to go into finding better therapies and
hopefully cures for MS and other diseases, but ever increasing costs of drugs puts a
tremendous burden on patients and on our healthcare system. If premiums continue to
increase, then there won’t be enough people able to afford health insurance and support
the system. While MS drugs are not the only culprits in skyrocketing healthcare costs,
their strange anti-competitive pricing is indicative of the problems associated with
unregulated pricing, and what is even more troubling about the lack of regulation is that
there is no end in sight to these price increases.
There is nothing legally stopping drug manufacturers from continually increasing
their prices, and it is very difficult for patients, doctors and insurers to have any impact
on prices without sacrificing patient outcomes. Due to the lack of regulation on the drug
industry’s price setting, unless there is some evidence of collusion among the
manufacturers, there is really no way to stop them from continually raising prices, and so
far there is no evidence of collusion except the strange price trends. Without this there is
currently no real regulatory authority to restrict these price increases. Furthermore, as
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mentioned before, patients and for the most part insurers have no collective means of
demanding lower prices. While insurers (besides Medicare) can bargain for lower prices
or demand rebates for drugs, it is very difficult to negotiate lower prices without
sacrificing patient outcomes. An insurer is unlikely to be able to negotiate lower prices
on all the MS drugs on the market because most likely negotiations involve some sort of
price preferential, where the insurer agrees to give preference to one brand over another
on their formulary. This is a sacrifice of patient outcomes because patients all respond
differently to different drugs and the insurer preference drugs may not be the most
effective for every patient.
A further problem with the way prices are set is the use of rebates, which must be
negotiated by insurers and thus excludes Medicare. Medicare, and thus the taxpayer,
pays a higher rate for drugs than any other payer. By setting high prices but allowing
negotiation the drug companies are essentially discriminating against Medicare. While it
is true that it is Congress that made this rule for Medicare, and pharmaceutical companies
are just exploiting it, the fact is that the pharmaceutical companies lobbied Congress
heavily to ensure that Medicare was denied bargaining power. Thus the industry has
made a loop-hole for itself that allows them a large customer base (the largest of all the
public and private insurers) that is forced to pay whatever price they set. This creates a
gigantic burden for our public health care systems which are on the verge of bankruptcy
and are shifting more and more burden on patients to pay for care.
Which brings us to the last problem: the unheard voice of the patient in price
setting. There has been much public outcry about the cost of drugs in this country, and
while this public image crisis has led to changes in some products, most drugs remain
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high priced and companies continue to point to rebates, or payment plans, or coupons that
reduce co-pays, and the systemic problem remains. The sad fact is that while patients
and doctors can point to unfair prices and attempt to raise public awareness, they have no
bargaining power themselves. Doctors and patients can educate themselves on prices and
search for low cost alternatives, but in cases like MS where no alternative exists patients
are forced to pay up. The healthcare system is unique because there is no option to walk
away from the negotiating table and no boycott option. Manufacturers and regulators
must come to some consensus on what a fair price is, and how much a company can over
charge in the name of investment and research.
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Chapter 4: Policies to reduce drug prices
The previous chapters have reviewed case studies in an attempt to understand
whether the prices we pay for drugs are justified. In general it seems that prices are
unjustifiably high, but there is some opacity in the pharmaceutical industry that makes it
difficult to fully understand whether prices are justified. This opacity comes with its own
ethical problems; by withholding information pharmaceutical companies are violating
their responsibility to create fair access. Patients and buyers have the right to information
about the products they are buying, including information about how prices are set.
Thus, even if we cannot determine whether all high prices are unjustified, it is clear that
the pharmaceutical industry is not living up to its ethical obligations. Furthermore,
whether or not prices are unjustifiably expensive the fact remains that pharmaceuticals
are unaffordable for many Americans; thus the American health system is not living up to
its obligation to provide equitable access to drugs. There is plenty of blame to be shared
for inequitable access; many pharmaceutical companies are taking advantage of
loopholes and other problems with our health policies, but the blame for allowing
companies to do so is shared among the entire American population and government.
Without the unregulated system that exists in America pharmaceutical companies would
not be able to set high prices. Pharmaceutical companies are in the business of making
profit, and it is the job o the government to protect patients and consumers from unethical
practices.
Thus the responsibility for bringing down costs rests with the government. There
are several policy actions that could change the landscape of prescription drug pricing.
These actions fall roughly into three categories: 1) enforcement of current regulations, 2)
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creation of new legislation, or 3) amending old legislation. These proposals include
policy recommendations as well as descriptions of some initiatives that have already been
taken or attempted. While they vary in their feasibility and difficulty, none of the
recommendations listed would require an extreme overhaul of our system, but rather
would be changes in the government regulation of pharmaceuticals and changes in the
practices of non-government stakeholders. I will begin with an overview of the steps that
could be taken and conclude with some progress that has already been made.

Possible actions:
There are several different policy avenues open to the federal government from
stricter enforcement of current policy to the repeal of ineffective legislation to the
passage of new legislation. While it should be noted that the latter two would require a
lot of political will, especially considering the recent track record of Congress in passing
new legislation, the current debate over the future of American Healthcare could provide
a forum for re-opening discussion of pharmaceutical regulation. A current hurdle for
many of these proposals will be President Trump’s Executive Order mandating that
federal agencies repeal two regulations for every regulation they add81. While this
mandate does not stand in the way of more strictly enforcing the regulations currently in
place it impedes the ability of agencies to add new regulation without going through
Congress. Furthermore, the Trump Administration has made many statements regarding
the high cost of drugs and the need to address the rising prices but those statements have
generally argued for reducing costs by deregulating the industry. While some of the
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policies recommended include the repeal of certain laws or parts of laws, these proposals
are to remove restrictions on government interference, not to remove regulations on the
pharmaceutical industry.

1. The existing laws and regulations that could be enforced include returning to
the original interpretation of patent law, use of antitrust law to regulate prices, and
tightening of FDA control over pharmaceutical advertising. In recent years the FDA and
many courts have weakened the restrictions on what can be patented and how patent
challenges can be litigated82.
a. Patent law was written to ensure that only novel, useful and non-obvious drugs
could receive patents and market exclusivity. But the patent office has allowed for
several means by which these requirements can be dodged. Patents are issued to drug
companies for features of drugs rather than the specific formula of the drug. This means
that when one patent expires, the company can apply for a patent for a different feature of
the same drug, thus obtaining a patent and 20 years of market exclusivity for absolutely
no innovation. This creates a problem for competition because when a feature rather than
formula is patented then it is harder to discern whether competitors entering the market
are truly novel, because there is no direct formula comparison to determine patent
infringement. Furthermore, allowing companies to get new patents for new uses of an
old drug rather than a truly new treatment is that it both limits the entry of generics for
both the new and old uses of the drug and limits the incentives for companies to invest in
research for truly new drugs. In order for a drug to receive patent protection and market
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exclusivity the drug should be new, and it should accomplish something new; it should
not just be better than a placebo but better than the existing treatments. To require true
novelty and improved utility in order to receive FDA approval would require new
regulation or law, but to require it for patent protection would simply require a changed
interpretation of existing regulations and would have a profound effect. Finally, the
Patent office should remove the incentives that pay patent officers bonuses based on the
number of cases they review. This practice leads to more patent approvals and a more
rushed process, because approving a patent actually takes less time than denying one83.
b. Antitrust law is another route of existing law that could serve to curtail the
rising costs of drugs. The practices of both generic and brand companies are in many
ways very anti-competitive, and the point of antitrust law is to ensure that unlawful
monopolies do not crop up. This could be pointed towards Big Pharma by limiting the
amount of mergers and buy-outs in the pharmaceutical industry and ruling against other
anti-competitive practices, like evergreening (constantly applying for new patents on old
drugs) and pay-for-delay (essentially bribing generic companies to delay the entry of
competition).
c. Finally, the FDA already has the ability to regulate pharmaceutical
advertising, but they currently use this power very sparingly. The FDA currently
regulates advertising only to make sure that companies describe the risks and side effects
of medications and do not make overtly false claims about the benefits. They could
however, take more serious steps to curtail the advertising efforts of pharmaceutical
companies. Limiting the advertising could mean requiring that pharmaceutical
companies state the comparative benefit that their drugs provide, or the price, or other
83
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pertinent information. Or the regulation could be limiting the kinds of claims that the
pharmaceutical company can make, today many companies make statements in ads about
the possible unintended positive effects of the drug such as weight loss or “increased
energy” which have limited basis in research. By using the regulating power already
given to the FDA, we could limit the amount of misleading claims that drug companies
make, and could possibly curb the demand for high priced drugs. If the ads stop falsely
driving up demand, companies might abandon them, which could pull down costs84.

2. In addition to enforcing the laws and regulations already in effect, new policies
could be enacted to limit the rise of drug prices. Changes could include the repeal or
amendment of some existing laws and the creation of new laws and regulations.
a. Laws that should be repealed or amended are the Medicare Prescription
Drug Benefit Reform of 2003 (Medicare Part D) and the Hatch-Waxman Act. Both of
these laws create loopholes for the pharmaceutical industry: limiting the power of the
government and private actors to resist price increases. Medicare Part D prohibits the
director of Medicare and Medicaid Services from bargaining to lower prices for Medicare
beneficiaries85. This is a giant loophole that accomplishes nothing except increasing
pharmaceutical profits at the expense of taxpayers and Medicare beneficiaries. Medicare
Part D also includes a provision that bans the re-importation of drugs from Canada unless
the Director of Health and Human Services gives explicit permission. This provision was
included with the explanation that safety standards could not be ensured if drugs were reimported through Canada. While there is virtually no evidence that drugs imported from
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Canada are more dangerous than drugs manufactured and directly sold in the US (and in
fact there is some evidence that Canadian imports are safer), no Director of HHS has used
their power to allow the importation of drugs from Canada. It should be noted here that
importing drugs is not a long term solution to rising drug costs, but it is an important tool
at our disposal to be used when prices on certain drugs becomes too high.
The Hatch-Waxman Act should also be repealed or amended to remove the
loopholes that exist for companies in the patent application and litigation processes86.
This is the law that allows old drugs to be re-patented for uses outside of the original
patent, which contributes to the practice of “evergreening,” increases costs and limits
innovation by making old drugs more profitable than new ones. This act has a further
problem in its regulation of patent litigation; under this law, whenever a patent challenge
is raised in court, an automatic 30-month window of market exclusivity is given to the
patented product, this serves only to limit the entry of generics and competitors which
might drive down prices, and increase the amount of frivolous law suits brought to
lengthen market exclusivity. Repealing or amending Hatch-Waxman would bring down
drugs costs by allowing for more entry of generic drugs.
b. In addition to the amendment of old legislation, new laws and regulations
could be created to bring down drug prices, there are possible steps to be taken at
virtually every stage of the pharmaceutical industry: from research to clinical trials to
patenting to regulating pricing and requiring transparency. To start, there are important
changes that can be made to the way clinical trials of drugs are conducted. Currently,
clinical trials only have to show that a drug has more benefit than a placebo and has
minimal harmful side effects, but new policy should be made requiring that drugs not
86
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only be tested against placebos, but against drugs already on the market for the same
purpose87. Along with this new policy would be several others to support it, including
making all study results public so that companies cannot bury negative results, and a
reorganization of the exclusivity period granted after patent and FDA approval. A
reorganization of the market exclusivity would mean a reduction in the amount of years
that a company was granted exclusivity (currently the period is 20 years), but the
exclusivity would begin after the drug finished clinical trials and received FDA approval.
This policy change would have several positive effects, it would lesson the amount of
time of market exclusivity, allowing for competition to begin sooner and prices to go
down, it would reduce the rush that is placed on clinical trials since they would no longer
eat into the exclusivity period and our knowledge of the drugs on market and our
consumer power would be increased since we would have more information about the
relative effectiveness of new drugs.
In order to accomplish these changes there would need to be some changes made
to the operations of the FDA. This is one of the more difficult policies to enact as it
would require more government investment in the FDA and would remove a lot of the
influence of drug companies on FDA practices. In order to make sure that the FDA is
serving the public by regulating drug companies and ensuring the development and
distribution of safe and useful drugs, we need to get the FDA out of the pockets of Big
Pharma. Currently the FDA is essentially paid by the pharmaceutical industry to review
their drugs as they are required to pay “user fees” to the FDA when they submit a drug
for approval. While this policy was enacted to ease some of the financial burden from the
federal government, its result has been that the FDA is now incentivized to review and
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approve new drugs88. Along with the reform of clinical trials, this would hopefully reduce
the amount of frivolous trials and refocus the industry on putting forward truly innovative
drugs, and with more funding from the government, the FDA could serve its purposes of
protecting people from harmful drugs and making sure that new drugs are useful and
worth the price we pay. In order to accomplish any of these FDA reforms we would first
need to remove those with ties to the pharmaceutical industry from the FDA advisory
boards, as these boards are currently populated with people who have conflicts of
interests and incentives to keep the FDA working for companies rather than people.
Once there is more adequate research into the comparative effectiveness of
various drugs and once Medicare can join the rest of the healthcare payers in advocating
lower prices, an “indication specific” model for pricing can be used. An indication
specific pricing model uses the comparative effectiveness of drugs to establish their
value89. Currently, any new drug on the market is likely to cost twice as much as an older
version whether it provides more patient benefit or not. While some hospitals, doctors
and insurers have taken the initiative to refuse to purchase and prescribe marked up drugs
with no added benefit, there is currently no national system for comparing the cost
effectiveness of drugs within the same class. This needs to be changed if all the various
payers and stakeholders are going to make informed decisions about which drugs to buy
and how much to pay.
The final step in creating new policy is accountability. Drug companies need to
be held accountable for their practices and the effects of their drugs. This starts with an
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opening of the books, drug companies need to be required to break down their expenses
more thoroughly and be more honest about their practices90. If some of the Research and
Development budget goes into market research rather than drug research, we have the
right to know and if “outreach and administration” includes lobbying and marketing
drugs to doctors and medical students, than we should have the right not to pay for those
expenses. Furthermore, companies should have outcome accountability, if a drug doesn't
work for a patient then that patient should not have to pay for the treatment they received.
This is a policy that has been successfully implemented in countries like Denmark, and
has reduced expenses and drug dependency in the healthcare industry, since companies
no longer push drugs on those who are unlikely to be helped by them.

Policy already initiated:
I have enumerated many ways by which we might bring pharmaceutical prices
down, or at least stop them from rising quite so rapidly. Currently, two bills await
hearings in the Senate Finance Committee, both aimed at lowering the costs Americans
face in purchasing prescription drugs. These two bills address some of the policy
proposals I outlined above, but they are both rather modest in their scope.
The first of these bills was introduced by Bernie Sanders, the Independent Senator
from Vermont and 2016 Democratic Presidential Candidate, and co-sponsored by
Representative Elijah Cummings, a Democrat from Maryland. This bill, “The
Prescription Drug Affordability Act of 2015” outlines several different strategies for
tackling the problem of rising drug prices including Medicare Part D negotiations, re-
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importation of prescriptions from Canada, Medicare and Medicaid rebates, prohibiting
“pay for delay,” harsher penalties for fraud committed by pharmaceutical companies and
requirements for more transparency in pharmaceutical costs and prices. Many of these
policy proposals have already come up in this investigation of drug prices, particularly
Medicare negotiation and prohibiting “pay for delay. 91”
The other piece of legislation, also stalled in committee, is a bi-partisan proposal
from Senator Wyden and Senator Grassley called “Reducing Existing Costs Associated
With Pharmaceuticals For Seniors Act of 2016.” While this bill is mostly targeting the
costs of drugs for seniors, it’s policies, particularly the call for transparency, could have
ripple effects in the broader landscape of drug prices. This bill would also increase the
rebates given to Medicare by drug companies, and the rebates given to seniors by
Medicare. Requiring greater rebates for Medicare (similar to those given to Medicaid)
would limit the costs to the federal government in providing prescription drug benefits,
and allow more money to give to seniors who still struggle to pay the co-pays for their
prescription drugs. This bill would also give the Director of HHS the ability to negotiate
directly with drug companies to bring down costs. This would be accomplished by
leveraging the power the Federal Government has as this single largest contributor to
pharmaceutical research92.
While these policies are not sweeping and do not comprehensively solve the
issues of the pharmaceutical industry, they all would make a difference in bring down
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costs or keeping them from going up. The bottom line is that something needs to be
done, because the current cost landscape is unsustainable. Many of these policies would
be very difficult to enact because the pharmaceutical industry has so much power in
Washington DC and there is very little consensus among representatives about what
causes high prices and what the solutions should be, thus the two bills mentioned have
each been waiting for a vote in the Senate Finance Committee for over a year.
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Chapter 5: Policy Recommendations By Case Study
I have reviewed some strategies for combating high drug prices, but now I will
put them into context by applying these policy changes to the EpiPen, Hepatitis C and
Multiple Sclerosis case studies. While none of the strategies I outlined would likely raise
prices, they would likely have different effects on different classes of drugs. While there
were certainly similarities between each of the cases, there were also slight differences in
the causes of the high prices. EpiPen, more than the other cases, owed much of its price
hikes to the costs of marketing and lobbying and to the secrecy surrounding the spending
of drug companies. Therefore the policies most effective in addressing the costs of
EpiPen, would be those curtailing the spending of companies on marketing and lobbying
and those requiring that spending breakdowns be made public. However, with Hepatitis
C Treatments, the biggest problems are the inability of all insurers to negotiate. Finally,
the largest problems with Multiple Sclerosis treatments are the lack of comparative
effectiveness information, and the resulting ability of companies to increase their prices
to match the cost of new drugs, even if there are no improvements to the drugs. While I
have highlighted the current problems of each drug and the corresponding policy
solutions, this is not to suggest that other policies would not work in the present or future
to bring down the costs of those drugs. For example, all of these drugs would or could
benefit from amendments to patent and FDA policies as well as more negotiating power.
As mentioned, EpiPen would benefit from policies that focus on marketing
spending and transparency. It is very difficult to know exactly how much it costs Mylan
to produce EpiPen, how much they spent on minor changes to the device and how much
was spent on marketing and “education”. However, while we do not know the exact

64

breakdown of Mylan’s EpiPen costs, we do know that there have been increases in
advertising and lobbying efforts of Mylan. This information, or lack there of, presents
some key problems and policy solutions. Until recently brand name EpiPen was
practically the only option for epinephrine auto-injectors, and so the public was forced to
pay whatever price Mylan set. Mylan has insisted that the $600 price was a fair one, but
has not backed up this claim by revealing any information about their costs. Without this
information, we cannot hold drug companies accountable for setting fair prices.
Furthermore, there is still the suspicion that most of the expenses leading to high prices
are advertising and lobbying costs, which creates several problems of its own. Companies
should not expect that the government, which buys its products, pay for the efforts to
lobby them and the American people. I see the process for addressing this as falling into
3 steps, first, drug companies like Mylan need to open up their books to the public so that
we can make informed decisions about our purchases and better understand what they are
paying for. Then, once this information is public, either the government should take
action to set caps on the amount of money that can be spent on lobbying and ads or use
the FDA to limit the amount of advertising done without setting price caps. If the
government chose not to take action after information was made public, then private
individuals or organizations could take action to use their purchasing power to demand
that drug companies prioritize innovation over marketing and bring down costs. In the
case of Mylan, after the public outcry over high prices, both Mylan and CVS released
generic auto-injectors. While this was not initiated by any government policy change, it
does show how public interest into prices can effect the actions of companies. Thus
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releasing the information about the spending of drug companies has the potential to
create public pressure for drug companies to change.
Unlike with EpiPen, the biggest challenge facing the price of the Hepatitis C is
the lack of bargaining power given to the state insurers. There is such a demand for the
newer curative treatments for Hepatitis C, that these medications could cost Medicare and
Medicaid $65 billion over the next 5 years, and have the potential to bankrupt many state
Medicaid programs. This has led to rationing of these treatments, with patients being
forced to wait until they have sustained irreversible liver damage until they can receive
their curative treatments. If Medicare and Medicaid were both able to use their
bargaining power at a national level, than they could bring down those costs, saving
money and providing more treatments to more people. The two Senate bills I already
mentioned would both accomplish this goal by allowing the director of the Health and
Human Services Department to negotiate for lower prices.
Finally, in the case of Multiple Sclerosis, the largest contributor to high prices is
the lack of comparative effectiveness studies for new medications. If each new multiple
sclerosis drug had to prove that it was better than the existing ones in order to get a
patent, then we may not have seen each new drug set its price above the existing ones, or
the existing drugs raise their prices to match the new drugs. If we knew the comparative
effectiveness of drugs than we could have value based pricing, where drugs that provide
more benefit can cost proportionally more, but drugs with equal or lesser value must
reflect that value in the price. In order to make value based pricing universal, the FDA
and patent office would need to make comparative effectiveness studies a part of the
process for getting approval. This would require some significant changes to law and
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regulation as well as more capital investment in the FDA. Without government oversight
of comparative effectiveness studies there is no way to make them universal, we instead
must rely on private studies, which are subject to bias since they are often funded by drug
companies. There must be some sort of government intervention in creating these studies
or we will continue to see prices rise without knowing for sure if the costs are tied to real
patient benefits.
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Appendix

A1: Organization of Economic Co-operation and Development review of drug
expenditure per capita in 29 developed nations. The US is on shown on the far left,
spending $1,026 per capita, compared the to OECD average (shown in red) of $515 per
capita.
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A2: The rise of prescription drug spending in the US from 2005 to 2014, with projections
to spending in 2024.
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A3: The OECD calculated expenditure on overall health services, public and private.

A4: Cost increase of 9 MS DMTs compared with average consumer product inflation and
the inflation of prescription drug costs specifically.
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A5: An overview of the increases in price for nine MS disease modifying drugs. The
initial cost is adjusted for inflation to the comparable cost if the drug was released in
2013, and compared to the actual cost in 2013.
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